Matches in Wikidata for { <http://www.wikidata.org/entity/Q91065023> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q91065023 description "artículu científicu espublizáu n'ochobre de 2018" @default.
- Q91065023 description "im Oktober 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91065023 description "scientific article published on 01 October 2018" @default.
- Q91065023 description "wetenschappelijk artikel" @default.
- Q91065023 description "наукова стаття, опублікована в жовтні 2018" @default.
- Q91065023 name "Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes" @default.
- Q91065023 name "Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes" @default.
- Q91065023 type Item @default.
- Q91065023 label "Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes" @default.
- Q91065023 label "Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes" @default.
- Q91065023 prefLabel "Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes" @default.
- Q91065023 prefLabel "Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes" @default.
- Q91065023 P1433 Q91065023-5C9E1177-4568-4BC8-9880-16325149C177 @default.
- Q91065023 P1476 Q91065023-ECD089C9-8FD8-4F97-A954-AA38AD65B19F @default.
- Q91065023 P2093 Q91065023-1A745A8A-D11D-4984-81B4-387C1A6A00DF @default.
- Q91065023 P2093 Q91065023-1AACB5C9-7F5A-43F7-940F-41A7784CE14F @default.
- Q91065023 P2093 Q91065023-906CD884-A45C-4F17-987B-174EE3B67416 @default.
- Q91065023 P2093 Q91065023-9E60F66F-1FBF-4836-84AB-FA86B0E12742 @default.
- Q91065023 P2093 Q91065023-9FDAED9B-D822-47A7-967A-495B1F3D2F9A @default.
- Q91065023 P304 Q91065023-D664105D-7A23-4E95-AFA2-E68F250BA67B @default.
- Q91065023 P31 Q91065023-9DFF5B31-5E67-40EA-9931-CFCFADAC34F1 @default.
- Q91065023 P433 Q91065023-A564F8CF-68A9-40B4-97DF-40968C29FE7B @default.
- Q91065023 P478 Q91065023-404C1406-4EA5-4567-BA30-2012BEB089EE @default.
- Q91065023 P577 Q91065023-77F59BE8-03E9-478C-9FD5-F5688E945CD4 @default.
- Q91065023 P698 Q91065023-74197945-A476-49BA-9710-52C2AC0F0622 @default.
- Q91065023 P932 Q91065023-0452F2E4-A567-4A26-B14D-A8EA8B153659 @default.
- Q91065023 P698 30647825 @default.
- Q91065023 P1433 Q26842282 @default.
- Q91065023 P1476 "Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes" @default.
- Q91065023 P2093 "Elizabeth Wu" @default.
- Q91065023 P2093 "Ivar S Jensen" @default.
- Q91065023 P2093 "Karen C Chung" @default.
- Q91065023 P2093 "Naomi C Sacks" @default.
- Q91065023 P2093 "Philip L Cyr" @default.
- Q91065023 P304 "380-386" @default.
- Q91065023 P31 Q13442814 @default.
- Q91065023 P433 "7" @default.
- Q91065023 P478 "11" @default.
- Q91065023 P577 "2018-10-01T00:00:00Z" @default.
- Q91065023 P698 "30647825" @default.
- Q91065023 P932 "6306103" @default.